Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.
Profil d’investissement
Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.
Strong fundamentals, but recent price decline raises caution.
Suivre dans le portefeuille
Transaction
Graphique des prix
Recommandation IA Prévision d’analyste Événement calendrier Signal positif Signal négatif Neutre / mise à jour Conserver / informatifB My buyS My sell
Changements de recommandation IA
Date
Avant
Après
Raison
2026-05-18 04:09
Conserver
Acheter
Strong fundamentals and positive short-term momentum.
2026-05-10 02:33
Acheter
Conserver
Weak momentum and high risk; mixed analyst signals.
2026-05-08 14:57
—
Acheter
Solid fundamentals but mixed momentum signals.
2026-05-08 05:27
Acheter
Acheter
Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29 02:48
Conserver
Acheter
Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17 02:54
Acheter
Conserver
Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09 03:16
Conserver
Acheter
Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22 07:36
Acheter
Conserver
Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06 08:57
Conserver
Acheter
Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29 08:45
Acheter
Conserver
Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.
La course entre les fabricants de médicaments pour développer des traitements innovants contre l'obésité s'intensifie, avec Eli Lilly et Novo Nordisk en tête du marché tandis que de nouveaux entrants explorent des thérapies alternatives. Cette compétition est cruciale car elle pourrait remodeler le paysage des médicaments pour la perte de poids et impacter les prix et l'accessibilité pour les patients.
The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.
Eli Lilly's stock continues to rise, driven by promising data on its obesity drug retatrutide, prompting analysts and investors to maintain their positions despite the stock's significant gains.
Pharmaceutical stocks are gaining momentum, with Eli Lilly leading the charge and reaching all-time highs, indicating a potential for broader sector strength that could benefit other major companies like Johnson & Johnson.
Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.
Last week's stock market experienced a significant downturn, primarily driven by disappointing earnings from major tech companies and a strong jobs report that diminished expectations for a Federal Reserve interest rate cut. This shift has raised concerns about the sustainability of recent market highs and the potential impact of increased stock supply from upcoming IPOs.
The recent decline in stock prices, particularly in the tech sector, presents a potential buying opportunity for investors, especially in chip stocks and AI-related companies, according to Jim Cramer.
Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.
Investors are witnessing a sector rotation from AI hardware to healthcare and financials, with notable movements in stocks like Goldman Sachs and CrowdStrike, indicating shifting market dynamics.
Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.
